MentionFox
Home › Executive changes › CG Oncology, Inc.
Leadership changes · CGON · SEC Form 8-K, Item 5.02

Leadership changes at CG Oncology, Inc. (2026)

Before you join, sell to or invest in CG Oncology, Inc.

MentionFox check on CG Oncology, Inc.: only 2 sources on file so far (checked 15 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/cg-oncology

Check CG Oncology, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about CG Oncology, Inc.?

Who joined and who left CG Oncology, Inc. (CGON)? 1 appointment reported from 2026-04-13 to 2026-05-26, each cited to the company's own filing.

Arthur Kuan was named President of CG Oncology, Inc. As of November 15, 2026, CG Oncology, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 13, 2026 to May 26, 2026, naming 1 appointment (Form 8-K, May 26, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies ↓

Sell to companies like CG Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
In (appointed)1
Latest filing2026-05-26

CG Oncology, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-13 to 2026-05-26. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as CG Oncology, Inc. files it.

Also on the record for CG Oncology, Inc.

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G/A, by James B. Tananbaum4.9% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by RTW Investments, LP9.7% of the class5%+ stakesSource
August 13, 2026Stake report, Schedule 13G/A, by Wellington Management Group LLP6% of the class5%+ stakesSource
July 27, 2026Stake report, Schedule 13G/A, by BlackRock, Inc.6.8% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by RTW Investments, LP8.3% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc.8% of the class5%+ stakesSource
March 26, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
November 12, 2025Stake report, Schedule 13G, by Wellington Management Group LLP7.2% of the class5%+ stakesSource
October 30, 2025Stake report, Schedule 13G/A, by The Vanguard Group8.62% of the class5%+ stakesSource
October 28, 2025Stake report, Schedule 13D/A, by Seven Fleet Capital Management LP2% of the class5%+ stakesSource
September 18, 2025Stake report, Schedule 13D, by Longitude Capital Partners IV, LLC6% of the class5%+ stakesSource
September 18, 2025Stake report, Schedule 13D, by Seven Fleet Partners LP2% of the class5%+ stakesSource

Selling to them or working with them? See who runs CG Oncology, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on CG Oncology, Inc. and the records around it.

CG Oncology, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on CG Oncology, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on CG Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on CG Oncology, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 13 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-05-26InPresident8-K, 2026-05-26
2026-04-13Reportednot named in the filing8-K, 2026-04-13

Who leads CG Oncology, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to CG Oncology, Inc.?

New leaders reset buying decisions — get the Full Report on CG Oncology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch CG Oncology, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the President at CG Oncology, Inc., with the record behind each one.

Find candidates like President at CG Oncology, Inc.

Every change, in the filing's words

Filed 2026-05-26 · 8-K

Appointed: Arthur Kuan, President

Kuan Appointment as President On May 20, 2026, the Company's Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete's separation.

Also stated in this filing

  • Bellete Separation On May 20, 2026, CG Oncology, Inc. (the "Company") and Ambaw Bellete, the Company's President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.
  • The Company thanks Mr. Bellete for his contributions and wishes him well in his next endeavors.
  • The Company has initiated a search for a Chief Commercial Officer.
Filed 2026-04-13 · 8-K

Reported

On April 13, 2026, CG Oncology, Inc. (the " Company ") appointed Jim DeTore as the Company's Chief Financial Officer.

Also stated in this filing

  • Mr. DeTore, age 61, has served as our Interim Principal Financial and Accounting Officer since November 2025 pursuant to a consulting agreement with Monomoy Advisors, LLC, and has been responsible for the Company's financial and accounting functions.
  • Prior to joining the Company, from June 2021 to June 2025, Mr. DeTore was Chief Financial Officer at Neurogastrx, Inc. Prior to serving at Neurogastrx, from March 2017 to May 2021, Mr. DeTore was an independent consultant providing chief financial officer services to a variety of early and mid-stage biotechnology and pharmaceutical companies, and from August 2016 to February 2017, Mr. DeTore was with Proteostasis Therapeutics, serving as Chief Financial Officer.
  • In addition, from November 2014 to February 2016, Mr. DeTore served as Chief Financial Officer at Bluebird Bio, Inc. Mr. DeTore holds a Bachelor of Science degree and a Master of Business Administration degree from Northeastern University.
  • In connection with his appointment as Chief Financial Officer, the Company and Mr. DeTore entered into an employment agreement, dated April 13, 2026 (the "Employment Agreement"), pursuant to which Mr. DeTore will receive an initial annual base salary of $520,000, less applicable withholdings, and will be eligible for an initial annual target bonus of 45% of his annual base salary.

Tools for this story

Each opens in a new tab, filled in for CG Oncology, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/cg-oncology
Last updated 2026-11-15
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
CG Oncology, Inc. names Arthur Kuan President (2026). MentionFox, 2026-11-15. https://mentionfox.com/executive-changes/cg-oncology